Should you consider this clinical trial for your stage 4 marginal zone lymphoma?
It's wonderful that you're exploring all your options! Clinical trials can offer access to promising treatment combinations, especially for advanced-stage lymphoma.
About the drugs in this trial:
Rituximab is a monoclonal antibody that Show Full Answer
Should you consider this clinical trial for your stage 4 marginal zone lymphoma?
It's wonderful that you're exploring all your options! Clinical trials can offer access to promising treatment combinations, especially for advanced-stage lymphoma.
About the drugs in this trial:
Rituximab is a monoclonal antibody that targets B cells (the cancer cells in lymphoma). It's commonly used for marginal zone lymphoma and is less toxic than traditional chemotherapy.
Acalabrutinib is a BTK inhibitor that blocks a protein B cells need to grow and divide. It's typically used for relapsed or refractory marginal zone lymphoma but may be studied earlier in treatment through trials.
Lenalidomide is an immunotherapy drug that helps your immune system fight cancer cells.
Why this combination matters:
This trial appears to combine targeted therapies that work differently to attack lymphoma cells. Clinical trials often test whether combining drugs is more effective than standard treatment alone. Questions to ask your oncologist:
* How does this trial compare to standard rituximab treatment for my specific situation?
* What are the potential side effects of combining these three drugs?
* Will I receive close monitoring throughout the trial?
* What happens if the trial treatment doesn't work for me?
A MyLymphomaTeam member shared: "Clinical trials helped me when I was stage 4. I was so sick last year. I'm still sick, but much better."
Your oncologist at MD Anderson knows your case best and can help you weigh whether this trial is right for you. Wishing you clarity in your decision!
April 21